Boehringer Ingelheim

This Phase 3 trial tests whether the oral drug nerandomilast can slow disease progression and improve symptoms in people with systemic sclerosis, a rare autoimmune disease that causes skin thickening and organ damage. About 448 adults with limited or diffuse systemic sclerosis wi…

This Phase 3 trial tests whether adding obrixtamig to standard chemotherapy helps people with advanced extrapulmonary neuroendocrine cancer live longer. About 390 adults will be randomly assigned to get either the combo or chemo alone. Obrixtamig is designed to help the immune sy…

This early-phase study tests a new drug (BI 1831169) combined with an existing immunotherapy (anti-PD1 antibody) in Japanese adults with advanced solid tumors that have spread or not responded to prior treatments. The main goal is to find the highest safe dose of the combination …

This study tests a pill called nerandomilast in adults with fibrosing interstitial lung disease (lung scarring) who are at risk of worsening. About 466 participants will receive either the drug or a placebo for at least 52 weeks. The goal is to see if nerandomilast can slow the d…

This study tests a medicine called nerandomilast in children aged 2 to 17 with fibrosing interstitial lung disease, a condition where lung tissue becomes scarred and stiff. The goal is to see if the drug is safe and how the body processes it, and to get early signs of whether it …

This study looks at how well the drug Jardiance works compared to other standard heart failure treatments in Chinese patients with a specific type of heart failure (HFrEF). Researchers will track about 5,000 adults to see which treatment better prevents heart failure hospitalizat…

This study will observe 3,000 adults in China with a type of heart failure called HFpEF who are starting the drug Jardiance. Researchers will track how many patients are hospitalized for heart failure or die from heart-related causes over time. The goal is to see how effective an…

This early-stage trial will test whether taking bosentan (a drug for blood pressure) changes how the body processes zongertinib (an experimental cancer drug). Sixteen healthy men will receive zongertinib alone and then with bosentan to compare drug levels. The study is not intend…

This early-stage study tests the safety and how the body handles multiple doses of an experimental drug called verducatib in 12 healthy Chinese adults aged 18 to 55. Participants take the drug by mouth for 4 weeks. The goal is to gather information to support future development o…